Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

08-122021

Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, tod...
06-092021

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)

Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, to...
06-022021

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients...

上一页 ···23 24 25 26 27 ··· 下一页